FDA clears Adherium ’ s inhaler sensor for OTC sales

The FDA gave Adherium (ASK:ADR) the go-ahead to launch over-the-counter sales of its Smartinhaler sensor for AstraZeneca‘s (NYSE:AZN) Symbicort asthma inhaler, the company touted last week. Adherium’s product installs directly onto a patient’s inhaler to monitor and boost medication adherence. The device records the time and date that a patient uses their inhaler and transmits the data to an app on the user’s phone or tablet. This feature allows users and physicians to track a patient’s medication usage patterns, according to Adherium. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears Adherium’s inhaler sensor for OTC sales appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Adherium Limited AstraZeneca plc Source Type: news